Cost-Effectiveness Analysis of Isavuconazole Versus Liposomal Amphotericin for the Treatment of Invasive Mucormycosis in Jordan

Author(s)

Naser A1, Bilbisi M2, Mousa R3, Aburmilah A4
1Isra University, Amman, Jordan, 2Abdali Medical Center, Amman, Jordan, 3The University of Jordan, Faculty of Pharmacy, Amman, AM, Jordan, 4Hikma laboratories, Amman, Jordan

OBJECTIVES: Invasive aspergillosis (IA) and mucormycosis (IM) continue to be life-threatening conditions associated with high rates of morbidity and mortality. In Europe, the standard of care for the initial management of mucormycosis is liposomal amphotericin B (combined with surgical debridement). Isavuconazole, a new antifungal agent with a broader pathogen spectrum, demonstrated effectiveness in the management IM patients. The aim of this study was to develop an economic model that examine the cost-effectiveness of isavuconazole versus liposomal amphotericin B for the treatment of IM in Jordan.

METHODS: We conducted a cost-utility analysis comparing isavuconazole (IV therapy for 15 days followed by 134 days’ oral therapy) and liposomal amphotericin B (IV therapy for 149 days) for the treatment of IM using a decision tree model. As direct costs associated with IM management, the cost of medications, the cost of medication administration, the cost of lab test monitoring, and hospitalization costs were calculated. The Jordanian Food and Drug Administration was contacted for information regarding the cost of medications. The cost of hospitalization was estimated from four main private hospitals in Amman, Jordan.

RESULTS: The total cost for the treatment of IM was estimated to be 17,595.1 Jordanian Dinar (JOD) (one JOD equals 1.41 USD) for isavuconazole and 109,001.8 JOD for liposomal amphotericin B. The estimated quality-adjusted life year (QALY) associated with isavuconazole treatment for IM was 5.6088 QALY. The estimated QALY associated with liposomal amphotericin B treatment for IM was 4.92 QALY. The incremental cost-effectiveness ratio (ICER) for the use of isavuconazole versus liposomal amphotericin B for the treatment of IM was -132,704.4 JOD per QALY gained.

CONCLUSIONS: Our model indicates that isavuconazole is a cost-effective treatment option for IM in Jordan. Our findings can assist clinicians and healthcare decision-makers in prescribing cost-effective medications for patients with IM. Thus, healthcare resources will be utilized more efficiently.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)

Code

EE487

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Drugs, Infectious Disease (non-vaccine)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×